MarketPulse

nivolumab

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Replimune Group, Inc.

Replimune's Melanoma Drug Rejected by FDA Despite Promising Trial Data

Replimune receives FDA rejection for RP1 immunotherapy despite 34% response rate in trials. Company plans layoffs, blames regulatory process.
REPLFDA rejectionComplete Response Letter
BenzingaBenzinga··Vandana Singh

Bristol Myers Wins FDA Approval for Opdivo Combo in Untreated Hodgkin Lymphoma

Bristol Myers wins FDA approval for Opdivo plus chemotherapy in untreated Hodgkin lymphoma. Stock declined 1.33% despite clinical success in Study CA209-8UT.
BMYCELGrFDA approvalclinical trial